Please assess the completion status of the following clinical trial:

Trial Title: Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Criteria:~* Pathologically confirmed newly diagnosed acute myeloid leukemia (AML)~* Subtypes M0, M1, M2, M4-7 disease~* No newly diagnosed acute promyelocytic leukemia (M3)~* Any of the following diseases:~* De novo disease~* Secondary AML~* Myelodysplasia (MDS)-related AML (MDS/AML)~* Treatment-related AML~* Previously untreated disease~* Patients who have received prior hydroxyurea alone or non-cytotoxic therapies for MDS (e.g., thalidomide, interferon, cytokines, 5-azacytidine, or revlimid) will be eligible for this study~* Must be considered ineligible for traditional antileukemia chemotherapy~* No hyperleukocytosis with ≥ 30,000 blasts/uL or rapidly rising blast count with projected doubling time of =\< 2 days~* Patients may receive hydroxyurea to lower blast count to \< 30,000 blasts/uL up to 24 hours before beginning tipifarnib and etoposide~* No active CNS leukemia~* No prior tipifarnib or etoposide~* No concurrent radiotherapy, immunotherapy, or other chemotherapy~* No concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, fosphenytoin, phenobarbital, primidone, carbamazepine, or oxcarbazepine)~* Patients may be changed to non-enzyme-inducing anticonvulsants and stabilized before starting study treatment~Inclusion Criteria:~* ECOG performance status 0-2~* Serum creatinine =\< 2.0 mg/dL~* SGOT and SGPT =\< 3 times upper limit of normal~* Bilirubin =\< 2 mg/dL~Exclusion Criteria:~* Active, uncontrolled infection~* Patients with infection under active treatment and controlled with antimicrobials are eligible~* Presence of other life-threatening illnesses~* Patients with mental deficits and/or psychiatric history that preclude them from giving informed consent or from following protocol~* Allergies to imidazoles (e.g., clotrimazole, ketoconazole, miconazole, or econazole)

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive 600 mg of oral tipifarnib twice daily on days 1-14 and 100 mg of oral etoposide once daily on days 1-3 and 8-10.
- Arm II (closed to accrual as of November 2008) (Type: EXPERIMENTAL): Patients receive 400 mg of oral tipifarnib twice daily on days 1-14 and 200 mg of oral etoposide once daily on days 1-3 and 8-10.

Based on this trial design, predict the completion outcome and termination type (if applicable).